Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products... Show more
The Stochastic Oscillator for CBT moved into oversold territory on May 22, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CBT's RSI Oscillator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CBT just turned positive on May 14, 2025. Looking at past instances where CBT's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CBT advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .
CBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on May 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CBT as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CBT entered a downward trend on May 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.868) is normal, around the industry mean (3.616). P/E Ratio (12.079) is within average values for comparable stocks, (34.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.312). Dividend Yield (0.017) settles around the average of (0.038) among similar stocks. P/S Ratio (1.330) is also within normal values, averaging (95.908).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
a supplier of organic chemicals
Industry ChemicalsSpecialty
A.I.dvisor indicates that over the last year, CBT has been closely correlated with WLK. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CBT jumps, then WLK could also see price increases.
Ticker / NAME | Correlation To CBT | 1D Price Change % | ||
---|---|---|---|---|
CBT | 100% | +0.93% | ||
WLK - CBT | 76% Closely correlated | -1.79% | ||
AVNT - CBT | 72% Closely correlated | N/A | ||
OEC - CBT | 69% Closely correlated | -1.80% | ||
IOSP - CBT | 65% Loosely correlated | +0.22% | ||
SCL - CBT | 64% Loosely correlated | N/A | ||
More |